Troponin in Cardiovascular Disease Prevention: Updates and Future Direction

Current Atherosclerosis Reports

Volumn 18, Issue 3, 2016, Pages 1-9

  Hoff, Jason ^a   Wehner, William ^b   Nambi, Vijay ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Atrial fibrillation; Biomarkers; Cardiovascular disease; Clinical risk scores; Coronary artery disease; Heart failure; High sensitivity troponin; Prevention; Risk factors; Troponin I; Troponin T

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; ROSUVASTATIN; SACUBITRIL PLUS VALSARTAN; TROPONIN; TROPONIN C; TROPONIN I; TROPONIN T; VALSARTAN; BIOLOGICAL MARKER;

ASYMPTOMATIC DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MORTALITY; PREDICTION; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; BLOOD; CARDIOVASCULAR DISEASES; RISK FACTOR;

BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS; TROPONIN;

EID: 84958252708     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-016-0566-5     Document Type: Review

References (70)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746–53.
2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220.
3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.
4. Wang T, Gona P, Larson M, Tofler G, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631–9.
5. Vasan R. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335–62.
6. Singh V, Martinezclark P, Pascual M, Shaw E, OʼNeill W. Cardiac biomarkers—the old and the new: a review. Coron Artery Dis. 2010;21(4):244–56.
7. Henry J, McPherson R, Pincus M, Abraham N. Henry’s clinical diagnosis and management by laboratory methods.
8. Harrison T, Longo D, Kasper D, Jameson J, Fauci A, Hauser S, et al. Harrison’s principles of internal medicine. New York: McGraw-Hill; 2012.
9. Antman EM, Grudzien C, Mitchell RN, et al. Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T. Am Heart J. 1997;133:596–8.
10. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50(7):e1–e157.
11. Lindahl B, Venge P, Wallentin L, for the FRISC Study Group. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation. 1996;93:1651–7.
12. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142(9):786–91.
13. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J. 1999;138:95–9.
14. Khan N. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation. 2005;112(20):3088–96.
15. Bessière F, Khenifer S, Dubourg J, Durieu I, Lega J. Prognostic value of troponins in sepsis: a meta-analysis. Intensive Care Med. 2013;39(7):1181–9.
16. Becattini C, Vedovati M, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116(4):427–33.
17. Faiz K, Thommessen B, Einvik G, Omland T, Rønning O. Prognostic value of high-sensitivity cardiac troponin T in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2014;23(2):241–8.
18. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22):2503–12. One of the three large multi-center prospective observational studies to determine the prevalence/importance of detectable Hs-Tn in a general asymptomatic population without preexisting CHD or HF. This study included the younger age group (age 30–65 years).
19. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123:1367–76. One of the three large multi-center prospective observational studies to determine the prevalence/importance of detectable Hs-Tn in a general asymptomatic population without preexisting CHD or HF. This study included the middle aged group (age 54–74).
20. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304(22):2494–502. One of the three large multi-center prospective observational studies to determine the prevalence/importance of detectable Hs-Tn in a general asymptomatic population without preexisting CHD or HF. This study included the older age group (age > 65).
21. Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113(16):1958–65.
22. Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol. 2008;52:450–9.
23. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–16.
24. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) biomarker project. Circulation. 2010;121:2388–97.
25. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin‐converting‐enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058–68.
26. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. Prevention of events with angiotensin converting enzyme inhibition trial I. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361:2538–47.
27. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.
28. Kavsak PA, Xu L, Yusuf S, McQueen MJ. High‐sensitivity cardiac troponin I measurement for risk stratification in a stable high‐risk population. Clin Chem. 2011;57:1146–53.
29. Peacock IV WF, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–26.
30. Jungbauer CG, Riedlinger J, Buchner S, Birner C, Resch M, Lubnow M, et al. High‐sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N‐terminal pro‐B‐type natriuretic peptide. Clin Chem Lab Med. 2011;49:1899–906.
31. Tentzeris I, Jarai R, Farhan S, Perkmann T, Schwarz MA, Jakl G, et al. Complementary role of copeptin and high‐sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011;13:726–33.
32. Tsutamoto T, Kawahara C, Nishiyama K, Yamaji M, Fujii M, Yamamoto T, et al. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure. Am Heart J. 2010;159:63–7.
33. Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012;125:280–8.
34. Nagarajan V, Hernandez AV, Tang WH. Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart. 2012;98:1778–86.
35. Kawahara C, Tsutamoto T, Sakai H, Nishiyama K, Yamaji M, Fujii M, et al. Prognostic value of serial measurements of highly sensitive cardiac troponin I in stable outpatients with nonischemic chronic heart failure. Am Heart J. 2011;162:639–45.
36. Apple F, Steffen L, Pearce L, Murakami M, Luepker R. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. Clin Chem. 2012;58(5):930–5.
37. McKie P, AbouEzzeddine O, Scott C, Mehta R, Rodeheffer R, Redfield M, et al. High-sensitivity troponin I and amino-terminal pro-B-type natriuretic peptide predict heart failure and mortality in the general population. Clin Chem. 2014;60(9):1225–33. doi:10.1373/clinchem.2014.222778.
38. Zeller T, Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel R, Tuovinen T, et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J. 2013;35(5):271–81.
39. Neeland I, Drazner M, Berry J, Ayers C, deFilippi C, Seliger S, et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. J Am Coll Cardiol. 2013;61(2):187–95.
40. Seliger S, de Lemos J, Neeland I, Christenson R, Gottdiener J, Drazner M, et al. Older adults, “malignant” left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure. JACC Heart Fail. 2015;3(6):445–55.
41. Pokharel Y, Sun W, de Lemos J, Taffet G, Virani S, Ndumele C, et al. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension. 2014;65(1):78–84. Important paper that showed how troponin levels are useful in assessing those with risk factors such as HTN.
42. Selvin E, Lazo M, Chen Y, Shen L, Rubin J, McEvoy J, et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014;130(16):1374–82.
43. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363–9.
44. Messer J. C-reactive protein and cardiovascular disease. Circulation. 2006;114(7):e253–4.
45. Miller V, Redfield M, McConnell J. Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk. Curr Vasc Pharmacol. 2007;5(1):15–25.
46. Lyngbaek S, Winkel P, Gotze J, Kastrup J, Gluud C, Kolmos H, et al. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. Eur J Prev Cardiol. 2013;21(10):1275–84.
47. Agarwal S, Chambless L, Ballantyne C, Astor B, Bertoni A, Chang P, et al. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) study. Circ Heart Fail. 2012;5(4):422–9.
48. D’Agostino R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53.
49. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail. 2008;1(2):125–33. doi:10.1161/circheartfailure.108.768457.
50. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111:499–510.
51. Nambi V, Liu X, Chambless L, de Lemos J, Virani S, Agarwal S, et al. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk: the atherosclerosis risk in communities study. Clin Chem. 2013;59(12):1802–10.
52. Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J. 2009;30:162–9.
53. Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic induced reversible myocardial ischemia. Clin Chem. 2008;54:1234–8.
54. Keller T, Munzel T, Blankenberg S. Making it more sensitive: the new era of troponin use. Circulation. 2011;123(13):1361–3.
55. Sawaya H, Sebag I, Plana J, Januzzi J, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375–80.
56. Sawaya H, Sebag I, Plana J, Januzzi J, Ky B, Tan T, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603.
57. Brush J, Cannon R, Schenke W, Bonow R, Leon M, Maron B, et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med. 1988;319(20):1302–7.
58. Picchi A. Coronary microvascular dysfunction in diabetes mellitus: a review. World J Cardiol. 2010;2(11):377.
59. Tsujita K, Yamanaga K, Komura N, Sakamoto K, Miyazaki T, Ishii M, et al. Impact of left ventricular hypertrophy on impaired coronary microvascular dysfunction. Int J Cardiol. 2015;187:411–3.
60. Folsom A, Yao L, Alonso A, Lutsey P, Missov E, Lederle F, et al. Circulating biomarkers and abdominal aortic aneurysm incidence. Circulation. 2015;132(7):578–85.
61. Schneider A, Rawlings A, Sharrett A, Alonso A, Mosley T, Hoogeveen R, et al. High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. Eur Heart J. 2014;35(27):1817–24.
62. Bansal N, Hyre Anderson A, Yang W, Christenson R, de Filippi C, Deo R, et al. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Soc Nephrol. 2014;26(4):946–56.
63. Pohlhammer J, Kronenberg F, Rantner B, Stadler M, Peric S, Hammerer-Lercher A, et al. High-sensitivity cardiac troponin T in patients with intermittent claudication and its relation with cardiovascular events and all-cause mortality—The CAVASIC Study. Atherosclerosis. 2014;237(2):711–7.
64. deFilippi C, de Lemos J, Tkaczuk A, Christenson R, Carnethon M, Siscovick D, et al. Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults. J Am Coll Cardiol. 2012;60(24):2539–47.
65. Ahmad T, Fiuzat M, Mark D, Neely B, Neely M, Kraus W, et al. The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. Am Heart J. 2014;167(2):193–202.e1.
66. Ridker P, Danielson E, Fonseca F, Genest J, Gotto A, Kastelein J, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.
67. Everett B, Zeller T, Glynn R, Ridker P, Blankenberg S. High-sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 2015;131(21):1851–60.
68. Jhund P, Claggett B, Voors A, Zile M, Packer M, Pieske B, et al. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail. 2014;7(6):953–9.
69. McMurray J, Packer M, Desai A, Gong J, Lefkowitz M, Rizkala A, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. Study that recently showed that therapy with neprilysin demonstrated a decrease in adverse clinical events with established HF. Study also incidentally found that the decrease in adverse clinical events was associated with troponin decrease as well.
70. Metra M, Cotter G, Davison B, Felker G, Filippatos G, Greenberg B, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program. J Am Coll Cardiol. 2013;61(2):196–206.